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Introduction
During the past decade, enormous improvements have been achieved in the treatment of metastatic melanoma. In particular, the immune checkpoint inhibitors, such as antibodies against cytotoxic T-lymphocyte-associated protein (CTLA)-4 and programmed cell death protein (PD)-1, have significantly improved the treatment efficacy in a subset of melanoma patients harboring wild type BRAF 1,2 . In addition, BRAF and MEK-kinase inhibitors achieved profound clinical responses in melanoma patients with BRAF V600 mutations 3 .
Even with these advances, only a fraction of melanoma patients responds durably to immunotherapy 4 . The therapy resistance was reported to be due to chronic inflammation and immunosuppression, tumor heterogeneity, as well as to lower numbers of somatic mutations encoding neo-antigens [5] [6] [7] [8] . Therefore, the attention of tumor immunologists has been shifted from shared tumor-associated antigens, to mutanome-encoded, patient specific neo-antigens 7 .
Nevertheless, tumor-associated antigens should not be forgotten since limitations in the neoantigen expression could be overcome by boosting immune responses via targeting tumorassociated shared antigens.
We attempted to improve the presentation of shared melanoma-associated antigens (MAA) by dendritic cell (DC)-based immunotherapy since the clinical impact of such immunotherapy has been limited so far 9 . Efficient major histocompatibility complex (MHC)peptide expression on DC and their activation determines the degree and quality of the T cell response. DC-based immunotherapies require improvements regarding (i) the origin and polarization of DC, (ii) the maturation stimuli by using better adjuvants, and (iii) the type and form of antigens to be loaded on DC 6 . To overcome these limitations, we have developed earlier a novel genetic platform for the induction of CD8 T cell responses specific for MAA, human glycoprotein (hgp)100 and tyrosinase related protein (TRP)-2 by DC vaccination 10 .
We showed that an efficient peptide presentation through human beta 2 microglobulin (hβ2m) can be coupled with constitutive toll-like receptor 4 (TLR4) signaling through the polypeptide product of a single gene by mRNA electroporation into bone marrow-derived DC. This modality was highly efficient in breaking immune tolerance by stimulating the activation of DC and antigen-specific CD8 T cell responses, which inhibited tumor growth and improved the overall survival in melanoma-bearing mice 10, 11 .
In this study, we broadened the repertoire of the hβ2m-platform for CD8 T cell induction by including two additional MAA, TRP-1 and tyrosinase (TYR). Moreover, we utilized this chimeric mRNA construct system to examine whether multivalent DC immunization is more effective to inhibit melanoma progression than current vaccination approaches with long peptides or peptide-pulsed DC. Importantly, we test our mRNA-based DC vaccine in two different genetically engineered mouse models (GEMM) that develop de novo tumors in a natural immune-proficient microenvironment 12 . Advanced tumors in RET-transgenic (RET-tg) and BRAF V600E mutated (BRAF) melanoma models closely mimic the histopathology and clinical development of their human counterparts as they are able to progress spontaneously toward metastatic disease 13, 14 . Since they are unresponsive to sole checkpoint inhibition they represent good preclinical model systems to test our vaccination strategy based on the presentation of shared MAA by DC [13] [14] [15] . Finally, to target the immunosuppressive melanoma microenvironment we applied either anti-PD-1 antibodies or paclitaxel (Pac) at ultra-low doses, which was reported previously by us to reduce the production of chronic inflammatory mediators and to inhibit myeloid-derived suppressor cells (MDSC) in the RET-tg model 16 .
We found that the immunization with our improved DC vaccine induced multi-antigenspecific effector T cells and long-lasting memory T cells, leading to a significant prolongation of the survival of tumor-bearing RET-tg and BRAF mice. Moreover, both combined therapies with ultra-low dose paclitaxel or checkpoint inhibitor further improved the survival, induced stronger CD8 T cell activation and significantly attenuated an immunosuppressive pattern of MDSC and regulatory T cells (Treg). Our data suggest that mRNA-based DC vaccination with shared MAA showed a strong therapeutic effect in two melanoma GEMM and could be Page 6 of 38 combined with other immunotherapeutic approaches to improve the efficacy of human melanoma treatment as an alternative to individualized neo-antigen vaccination.
Results

Chimeric β2-microglobulin molecule assembly
We have previously generated chimeric receptor constructs with MAA specific to human gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] and murine TRP-2 180-188 (both H-2D b binder) and described their anti-tumor activity in melanoma-bearing mice 10, 11 . To broaden the clinical potential of the constructs we included additional MAA such as TRP-1 455-463 (H-2D b binder) that was reported to confer anti-tumor immune responses 17 and TYR 360-368 , which was predicted by SYFPEITHI prediction software as an H-2D b binder 18 . Both peptides were assembled into the chimeric hβ2m-platform with the TLR4 and Kb anchors ( Supplementary Fig. 1A , B) as previously described 19 . The designation of new constructs is summarized in Supplementary Fig. S1C .
DC present the MHC-I constructs on the cell surface and induce cytotoxic T cells
The kinetics of MHC-I construct expression on the cell surface of bone marrow-derived DC was monitored by flow cytometry with anti-hβ2m antibodies. All constructs were found to be expressed on the DC surface for at least 48 h, although TRP-1-Kb and TYR-Kb constructs were expressed at higher levels than TRP-1-TLR4 and TYR-TLR4 ones ( Fig. 1A,   B ), which is consistent with previous observations 10 . We electroporated DC with mRNAconstructs containing Kb and TLR4 anchors for the same antigen at 1:1 ratio to ensure prolonged presentation via the Kb construct and DC maturation due to the constitutive intracellular TLR4 signaling. Upon electroporation, we observed a profound stimulation of IL-12 production by DC (similar to that induced by LPS) and no significant induction of IL-10 ( Fig. 1C ). Moreover, electroporated DC displayed an upregulation of CD80, CD86 and MHC class II expression comparable to the stimulation with LPS ( Fig. 1D-F ). This marker profile and strong IL-12 secretion supports the DC maturation, which is in line with our previous data 10 . In addition, the immunization with mRNA electroporated bone marrowderived DC led to the induction of antigen-specific cytotoxic T lymphocytes (CTL), which specifically killed melanoma target cells in vitro (Fig. 1G, H) . Thus, the new TRP-1/TYR-hβ2m-TLR4/Kb chimeric constructs electroporated into DC initiated a maturated phenotype and induced antigen-specific CTL.
mRNA-electroporated DC induce stronger CTL responses than peptide-loaded DC
To evaluate if TRP-1/TYR-hβ2m-TLR4/Kb chimeric constructs are superior to conventional, peptide-loaded DC in inducing specific CTL killing in vivo, we transfected DC with mRNA of TRP-1-hβ2m-TLR4/Kb (TRP-1-EP), TYR-hβ2m-TLR4/Kb (TYR-EP) or with the mixture of them (Mix-EP; TRP-1/TYR-hβ2m-TLR4/Kb) at 1:1 ratio. In parallel, LPS matured DCs were loaded with TRP-1 455-463 (TRP-1-PL), TYR 360-368 (TYR-PL) peptide or peptide mixture (Mix-PL). Electroporated unloaded DC (control) and OVA 257-264 peptideloaded mature DC (SIINF-PL) served as controls. The induction of CTL responses was studied upon the vaccination of mice with respective DC preparations using CTL in vivo killing assay. As seen in Fig. 2A , B, all three groups of mRNA-electroporated DC (EP) were able to elicit significantly stronger CTL responses than cells loaded with the respective peptides (PL). Moreover, mice vaccinated with mRNA-electroporated DC displayed significantly higher frequency of IFN-γ secreting and effector memory CD8 T cells in spleens upon in vitro restimulation than mice receiving peptide-loaded DC vaccines ( Fig. 2C, D) .
mRNA-transfected DC are superior to peptide-loaded DC in conferring anti-tumor effects
We next investigated the impact of the TRP-1/TYR DC vaccine on melanoma progression in RET-tg mice, which closely resembles human melanoma regarding histopathology and clinical development 14 . As seen in Fig. 3A , the immunization with DC electroporated by the mixture of TRP-1/TYR-hβ2m-TLR4/Kb mRNA (Mix-EP) resulted in a significantly improved survival as compared to mice treated with empty DC (control group). However, the survival of mice treated with DC containing a single antigen showed only a trend for the survival prolongation, which was not significant (Fig. 3A) . Since several clinical studies described promising effects with the long-peptide vaccination combined with adjuvants 20,21 , we applied the vaccination with peptide loaded DC (Mix-PL) as well as with long peptide mix (LP, TRP-1448-472 , TYR 353-377 ) combined with anti-CD40 mAb and poly:IC for effective T helper cell-mediated costimulation 22 similar to our hβ2m-TLR4 constructs. Survival monitoring displayed a non-significant tendency for improved survival for the long peptide mix (LP+CD40+P:IC) vaccinated group (Fig. 3B ). In contrast, vaccination with the mRNAelectroporated DC vaccine (Mix-EP, P < 0.01) showed a more profound and significantly higher survival prolongation than peptide-loaded DC (Mix-PL, P < 0.05; Fig. 3B ).
Consequently, the mRNA-electroporated DC vaccine (Mix-EP) showed an increased therapeutic efficiency as compared to all other vaccinated groups.
Improved DC vaccine stimulates T cell-mediated immune responses
Analyzing the activation status of tumor-infiltrating T lymphocytes upon mRNAelectroporated DC vaccination, we demonstrated an increased frequency of IFN-γ producing CD8 T cells in the group immunized with TRP-1/TYR-Mix group (Mix-EP) as compared to the control group ( Fig. 3C ). Furthermore, the expression of T cell activation markers such as TCR δ-chain ( Fig. 3D ), CD69 ( Fig. 3E ), PD-1 ( Fig. 3F ) and the proliferation marker Ki67 MDSC from the Mix-EP vaccinated group (Fig. 4B ). In addition, the frequency of PD-L1 + MDSC was significantly decreased (Fig. 4C ). Similar to MDSC, the frequency of Treg was not changed in the Mix-EP vaccinated group (Fig. 4D ). However, we demonstrated a reduced expression of Ki67 and CD39 on these cells (Fig. 4E, F ). This suggests that mRNA-based DC vaccination could stimulate powerful CD8 T cell responses without concomitant activation of immunosuppressive cell populations. We even detected a decrease in the immunosuppressive pattern of tumor-infiltrating MDSC and Treg.
Combination of multivalent DC vaccination with ultra-low dose Pac stimulates antitumor responses in melanoma-bearing mice
Our previous studies showed that treatment of melanoma-bearing RET-tg mice with Pac at non-cytotoxic, ultra-low doses reduced chronic inflammatory factors and immunosuppressive MDSC functions 16 . In addition, it was suggested that the vaccination with multiple antigens leads to improved clinical outcomes 20, 21 . Therefore, we electroporated DC with a quadrupleantigen mRNA Mix (Q-Mix), containing TRP-1/TYR-hβ2m-TLR4/Kb constructs and previously described hgp100/TRP-2-hβ2m-TLR4/Kb constructs 10, 11 and treated melanomabearing mice from RET-tg and BRAF models in combination with ultra-low dose Pac ( Supplementary Fig. 1C , D). Multivalent DC vaccination (Q-Mix) significantly prolonged mouse survival in both models ( Fig. 5A, B ). As expected, therapeutic effects of vaccination were more profound when combined with ultra-low dose Pac (Q-Mix+Pac).
Analyzing immune cells in melanoma lesions, we demonstrated a significant increase in the frequency of IFN-γ + CD8 T cells upon Q-Mix DC vaccination alone or in combination
with Pac ( Fig. 5C and F ). In addition, an elevated frequency of antigen-specific tumorinfiltrating CD8 T cells in treated RET-tg mice was detected by tetramer staining (Supplementary Fig. 2A, B ). Furthermore, Q-Mix DC vaccination alone or combined with Pac significantly increased the frequency of tumor-infiltrating CD8 T cells (Supplementary Supplementary Fig. 8F, G) . In addition, the amount of activated conventional CD4 T cells was significantly increased ( Supplementary Fig. 8H ). These results indicate that the combination of DC vaccination with chemo-modulating agents (such as ultra-low dose paclitaxel) or with the checkpoint inhibition could provide a significantly improved antitumor effect in preclinical melanoma GEMM.
Discussion
Limited mutation load and, therefore, reduced efficacy of neo-epitope based personalized immunotherapy along with profound immunosuppression in the tumor microenvironment may be major reasons of the resistance of a significant fraction of patients to current treatments with negative immune checkpoint inhibitors 1, 4, 24 . Moreover, insufficient tumor antigen processing and presentation by DC may hamper the development of tumor-specific T cells 25 .
Many therapies aiming to boost T cell responses are now in use 26, 27 and CD8 T cells are the key players in anti-tumor immune responses since increased intra-tumoral infiltration of these cells was reported to correlate with a better patient outcome 28 . Vaccinations using neoantigens are now in the focus since they could be promising in breaking immune tolerance 21 .
However, approaches using the immunization with multiple shared tumor-associated antigens could be very efficient since the multivalent T cell response reduces the possibility of tumor escape in a larger cohort of patients 20 . In addition, this vaccination strategy represents a promising approach for the treatment of tumors with low mutational load 7 . Usually, immunotherapies include single agents that target individual steps in the anti-tumor immune response. However, such monotherapies are unlikely to overcome complex mechanisms that impede anti-tumor immunity in patients 8 . Therefore new multivalent and combinatorial therapies are tested now in some ongoing clinical trials that include the targeting of several immune cell populations 5, 8 .
Here we applied immunization with shared MAA based on our recently developed genetic mRNA cancer vaccines 10, 19 , which was combined with chemo-modulation or checkpoint inhibition to tackle the immunosuppressive tumor microenvironment. We opted for mRNAbased DC vaccination since DC can stimulate both adaptive and innate anti-tumor immune responses and were already intensively used for cancer immunotherapy 27, 29 . Moreover, tumorassociated antigens could be delivered to DC by loading as peptides or recombinant proteins or by mRNA transfection 30 . Importantly, mRNA cannot integrate permanently into the genome, and therefore, has no oncogenic potential 31 . In addition, mRNA may act as an adjuvant by providing costimulatory signals, for example, via TLR 32 , yet only few studies coupled constitutively active TLR4 for this purpose 33, 34 . We have previously shown that a universal MHC-I chimeric mRNA construct DC vaccine, which couples the presentation of MAA hgp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] and TRP-2 180-188 and the stimulation of DC via constitutively active TLR4 domain, inhibited melanoma growth and improved mouse survival 10, 11 .
In this study, we designed two additional MAA MHC-I constructs to develop a multivalent (quadruple) DC vaccine for melanoma immunotherapy. We have characterized the newly designed constructs encoding for TRP1 [455] [456] [457] [458] [459] [460] [461] [462] [463] and TYR 360-368 as new MHC-I restricted MAA for this hβ2m-platform. We showed that the immunization with DC expressing the mix of TRP1 / TYR-hβ2m-receptors resulted in stronger anti-tumor effects in the RET-tg melanoma mouse model as compared to TRP1 / TYR long-peptide-mix vaccination with agonistic CD40 antibodies and the poly:IC adjuvant. Interestingly, the application of these adjuvants with mutated peptides was reported to induce a significant delay in the growth of MC-38 mouse colon adenocarcinoma 35 . Furthermore, local intratumoral administration of adjuvants might be more effective, limiting systemic inflammation yet activating APCs locally 36 . However, a direct comparison of different vaccination strategies is difficult, especially with regards to the adjuvant composition, the dose, and the application route (local versus systemic) 37 .
A better efficiency of our mRNA-based DC vaccination compared to long peptide vaccination could be due to the fact that peptides need protection from degradation in vivo to reach antigen presenting cells (APC) as recently demonstrated 38 . Moreover, longer antigen presentation by DC in our system could influence the expansion of T cells and their differentiation to memory cells 39 , enhancing thereby the vaccination efficiency.
To address the question whether the quadruple antigen-mix vaccination could further enhance the therapeutic efficiency, we vaccinated mice from two melanoma GEMM (RET-tg and BRAF) with electroporated DC containing TRP-1-, TYR-, hgp100-and TRP-2-hβ2mreceptors. Indeed, we found a further increase in mouse survival associated with an enhanced accumulation of antigen-specific tumor-infiltrating CD8 T cells and a stronger induction of memory T cells in both GEMM. Since MAA were described to be overexpressed in BRAFmutated melanoma-bearing mice 13 and melanoma patients carrying the BRAF V600E mutation 40 , this DC vaccination strategy using shared MAA could open additional therapeutic options for these melanoma patients in addition to the treatment with BRAF/MEK inhibitors 41 .
Although some Treg and MDSC markers were reduced already upon vaccination with the quadruple-mix DC vaccine, we decided to combine this treatment with the targeting of immunosuppressive tumor microenvironment. The impact of Pac on immunosuppressive myeloid cells was already described 16, 42 . Other studies reported a selective impairment of Treg by Pac in tumor-bearing mice 42, 43 . We demonstrated previously that melanoma progression in RET-tg mice was associated with the activation of MDSC and accumulation of chronic inflammatory factors 15 , and Pac at ultra-low doses inhibited MDSC activity and reduced production of chronic inflammatory factors, leading to the prolongation of mouse survival 16 . Moreover, the application of ultra-low dose Pac increased T cell responses upon peptide vaccination 44 . As expected, we showed here, that the administration of the quadruple DC vaccine with ultra-low dose Pac resulted in an improved survival of melanoma-bearing RET-tg and BRAF mice compared to any single therapy. Importantly, we observed also a significant decrease in intratumoral concentrations of IL-10, TNF-, IL-6 and VEGF that are known to be involved in the expansion and stimulation of MDSC 23 . Chronic inflammatory factors were already described as prognostic markers in cancer patients 45, 46 and their neutralization could lead to the restoration of anti-tumor immune responses 15, 16 . Here, upon the combined treatment, mice displayed a stronger activation of antigen-specific CD8 T cells and an induction of long-lasting memory CD8 T cells, which is considered to be a hallmark of efficient cancer vaccination 47, 48 .
Next, we investigated therapeutic effects of the DC vaccination combined with anti-PD-1 antibodies that are currently applied for the treatment of advanced melanoma patients.
Previous preclinical studies showed a therapeutic efficiency of vaccination together with negative immune checkpoint inhibitors, whereas either single therapy was ineffective 49, 50 . In line with these studies, we showed that the multivalent DC vaccine together with anti-PD-1 antibodies induced a more powerful immune response and prolonged survival of melanoma bearing RET-tg than DC vaccination or anti-PD-1 antibodies alone. Importantly, this combinatorial immunotherapy caused a reduction of frequency and activation markers of tumor-infiltrating Treg. This observation is in agreement with the study on melanoma patients, showing that the PD-1 blockade resulted in the down-regulation of Foxp3 expression in Treg and induced an impairment of their immunosuppressive functions 51 . Furthermore, we found that treated mice displayed decreased Arg-1 and PD-L1 expression as well as NO production. Similar reduction of Arg-1 expression and suppressive activity of MDSC was shown by others upon the blockade of PD-1 or PD-L1 in mice with ovarian carcinoma 52 .
Taken together, we demonstrated in two melanoma GEMM, which closely resemble the situation in melanoma patients, a high anti-tumor efficiency of the improved, multivalent hβ2m-mRNA-based DC vaccine platform using shared MAA that induce potent tumorinfiltrating antigen-specific effector and memory CD8 T cells, without stimulating immunosuppressive cells like MDSC and Treg. The hβ2m-mRNA-based system is safe, modular and can be applied on multiple tumor antigens in different cancers. In addition, when combined with approaches targeting the immunosuppressive tumor microenvironment (such as ultra-low dose Pac or anti-PD-1 antibodies) this strategy resulted in stronger anti-tumor effects associated with further CD8 T cell stimulation and reduction of immunosuppressive cells. Based on our preclinical data, we suggest that such combinatorial strategy could significantly increase the efficiency of existing immunotherapies of patients with melanoma and other tumors.
Materials and Methods
Mice C57BL/6 mice expressing the human RET oncogene in melanocytes (RET-tg mouse model) 14 All cells were cultured at 37°C, 5%CO 2 .
Peptides and antibodies
The short MHC class I restricted peptides OVA 257-264 (SIINFEKL), modified TRP-1 [455] [456] [457] [458] [459] [460] [461] [462] [463] (AAPDNLGYM), TYR 360-368 (SSMHNALHI), hgp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] 
In vitro mRNA transcription
Template DNA cloned in the pGEM4Z-A64 vector was prepared using NucleoBond Xtra Maxi Plus DNA purification system (Macherey-Nagel) and linearized via the SpeI restriction site positioned at the 3' end of the poly (A) tract of the vector. One µg of linear plasmid was used for in vitro mRNA transcription with T7mScript Standard mRNA Production System (CELLSCRIPT). The concentration and quality of the mRNA was assessed by spectrophotometry.
Generation of BMDC from murine bone marrow cells
Murine bone marrow-derived DC were generated as described 53 with minor modifications.
Briefly, bone marrow cells from femurs and tibiae of 4-5 weeks old C57BL/6 female mice were cultured in BMDC growth medium, consisting of RPMI (Invitrogen) supplemented with 10% heat-inactivated FCS, 2 mmol/L glutamine, 1 mmol/L sodium pyruvate, 0.1 mmol/L nonessential amino acids, 100 U/mL penicillin, and 100 μg/mL streptomycin (Thermo Fisher Scientific) and 200 U/ml rmGM-CSF (Prospec). On day 8, non-adherent cells were harvested and cultured in fresh BMDC growth medium containing 100U/ml recombinant mGM-CSF for 24 h. BMDC were kept immature prior to β2m-mRNA electroporation or were maturated by addition of 1 µg/ml of lipopolysaccharide (LPS, Sigma-Aldrich) for another 24 h prior to peptide loading.
mRNA electroporation of bone marrow-derived DC
2.5x10 6 DC were washed twice and resuspended in OptiMEM medium containing 10-20 µg transcribed mRNA (5 g mRNA/ construct) and electroporated in a 2 mm cuvette using Gene Pulser Xcell™ Electroporation Systems (Bio-Rad) at 400V, 0.9ms, one pulse. Cells were resuspended in 5mL BMDC growth medium with 100U/ml recombinant mGM-CSF and incubated for 6 h at 37°C, 5% CO 2 for β2m-mRNA-construct expression.
Therapy experiments
RET-tg mice that spontaneously develop skin melanoma were selected for the treatment at the age of 5-6 weeks when the mice displayed palpable skin tumors. BRAF mice were injected intradermally with 32 mM hydroxytamoxifen (4-HT). 21-28 days later, we initiated the therapy of animals, which developed highly pigmented, palpable melanoma skin lesions with the size of 5-10 mm 3 . All melanoma-bearing mice were vaccinated with 0.5x10 6 cells/in 200 μL cell suspension intraperitoneally (i.p) three times in weekly intervals using DC either electroporated with respective β2m-mRNA (5 g/construct) or loaded with short peptides (30 g/peptide). In some experiments, tumor-bearing mice were treated i.p. with ultra-low dose (1 mg/kg) Pac (Hexal). In other set of experiments, melanoma-bearing mice were injected i.p. four times every 3 days with 250 g/mouse anti-PD-1 antibodies (clone 2A3) or isotype control antibodies (clone 2A3, both from BioXcell). Other tumor-bearing mice were treated subcutaneously 3 times in weekly intervals with mixture of 50 g long peptide each (LP, TRP-1 448-472 , TYR 353-377 ), 30 μg anti-CD40 mIgG1 antibodies, and 100 μg poly:IC (Invivogen) as adjuvants.
CTL in vitro killing assay
Ten days after the last vaccination mice were sacrificed and splenocytes were excised and sensitized with 50 µg/ml of respective peptide for 5 days. Afterwards lymphocytes were separated by Lympholyte-M gradient (Cedarlane) and seeded at concentrations of 5x10 5 -6x10 4 cells/well. 5x10 3 target cells (B16F10.9, B16MO5 and 3LL-D122 cell line expressing no MAA serving as a negative control) were labeled with 35 S methionine (Perkin Elmer) and co-cultured with sensitized lymphocytes in different target/effector cell ratios for 5 h at 37°C. 
Bio-Plex assay
Snap frozen skin tumor samples were mechanically disrupted and treated with lysis solution (Bio-Rad). Protein amount in lysates was determined using Pierce BCA protein assay kit (Thermo Fisher Scientific). Inflammatory factors were measured by multiplex technology 
Preparation of single cell suspensions
Spleen, lymph nodes and tumor lesions were mechanically disintegrated by a plunger and filtered through a 40 µm cell strainer. After the depletion of the erythrocytes by ammonium chloride lysis, cells were washed with FACS buffer (PBS+0.5% BSA+0.1% Na-Azide) and resuspended in an appropriated buffer for further analysis.
Flow cytometry
After 10 min treatment with FcγII/III block (eBioscience), cells were incubated for 30 min at 4°C with directly conjugated mAbs. To measure intracellular IFN-γ production, CD8
T cells were restimulated in vitro with 30 g/mL specific peptide or 5 g/mL irrelevant peptide (SIINFEKL). Stimulation with 50 ng/ml phorbol myristate acetate (PMA) and 750 ng/ml Ionomycin (Sigma Aldrich) were used as positive control. After 2 h of restimulation, 2 µM Brefeldin A and 3 g/ml Monensin (both from eBioscience) were added. For fixation and permeabilization, the Foxp3 fixation/permeabilization kit was used followed by the treatment with FcγII/III block (both from eBioscience) for 10 min. Then, cells were incubated with antibodies for flow cytometry for 30 min at 4°C. In some experiments, cells were stained for 2 h with streptavidin-PE-conjugated H-2-K b mouse MHC-class I tetramers followed by anti-CD8-APC mAbs. To exclude dead cells, 7-AAD (BD Bioscience, San Jose, USA) was added.
Acquisition was performed by FACSCanto II with FACSDiva 6.0 software (BD Bioscience).
FlowJo software (Tree Star) was used to analyze at least 500,000 events.
Statistical analysis
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Statistical analysis was performed using GraphPad Prism software. Data are presented as the mean ± SD. Statistical significance was assessed using the nonparametric Mann-Whitney test or Kruskal-Wallis according to data requirements. Bonferroni and Dunn's posttests were followed according to their appropriate use. Survival curves were generated using the product limit method of Kaplan and Meier, and comparisons were made using the log-rank test. P < 0.05 was considered as statistically significant. 
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